JSJ. Timothy Stout

J. Timothy Stout

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


J. Timothy Stout has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Recombinant Filaggrin Is Internalized and Processed to Correct Filaggrin Deficiency

    by Thomas E. Stout, Trevor McFarland, John C. Mitchell, Binoy Appukuttan, J. Timothy Stout


  • Surgical Approaches to Gene and Stem Cell Therapy for Retinal Disease

    by J. Timothy Stout, Peter J. Francis

    Gene and cell therapy holds tremendous promise for treating a variety of acquired and inherited disorders of the retina that impact on vision. Much has been written about the impact of vectors in delivering genes to cells of the retina in vivo. A critically important component of these kinds of therapies is the procedure used to introduce the cells or vectors. Drs. Stout and Francis provide a broad overview of gene and cell therapies for diseases of the retina, focusing on the procedures that could be used for delivery.


  • Angiogenic Gene Therapy for the Treatment of Retinopathies

    by Jacob M. Jones, Trevor McFarland, J. Timothy Stout

  • Open Access

    Identification of Novel Alternatively Spliced Isoforms of RTEF-1 within Human Ocular Vascular Endothelial Cells and Murine Retina

    by Binoy Appukuttan, Trevor J. McFarland, Michael H. Davies, La-Ongsri Atchaneeyasakul, Yi Zhang, Bobby Babra, Yuzhen Pan, James T. Rosenbaum, Ted Acott, Michael R. Powers, et al.

    Purpose. Identification of transcription factors that regulate the transcription of the vascular endothelial growth factor (VEGF) gene may facilitate understanding of the etiology and progression of ocular neovascular diseases. The purpose of this study was to determine whether transcriptional enhancer factor 1-related (RTEF-1) was present within ocular vascular endothelial cells and whether it played a role in the control of the transcription of the VEGF gene. methods. Primary cultures of human retinal vascular endothelial cells (RVECs) were maintained under normoxic or hypoxic conditions before isolation of mRNA. RT-PCR was performed to detect RTEF-1 transcripts. Amplified products were cloned into an expression plasmid. Human VEGF promoter and deletion constructs were cloned into a pSEAP reporter vector. Various RTEF-1 isoforms and VEGF promoter constructs were coelectroporated into human cells, and reporter expression levels were determined. Retinal tissue from a mouse model of retinopathy of prematurity (ROP) was analyzed by RT-PCR for the presence of RTEF-1 transcripts. results. Full-length 1305-bp and novel 936-bp RTEF-1 transcripts were identified in cultured human RVECs under normoxic conditions. A novel 447-bp isoform was present in cells maintained in a hypoxic environment. Four of the 11 translated exons predicted to code for the 1305-bp product were spliced out of the 936-bp transcript. The 1305-bp product enhanced expression from the VEGF promoter 4-fold greater than background, whereas the 936-bp and the 447-bp isoforms enhanced expression 3× and 12×, respectively. Analysis with deletion promoter constructs determined that all isoforms required the presence of Sp1 elements for efficient activation and that the hypoxia response element (HRE) was not essential for enhancement. Transcripts for novel RTEF-1 isoforms were also identified in neural retinal tissue of mice. Different murine-specific isoforms were present at different stages of postnatal development. conclusions. Novel RTEF-1 transcripts are present within human ocular vascular endothelial cells and mouse neural retina during normal and ROP development, and alternatively spliced products are produced under hyperoxic and hypoxic conditions. Alternative spliced variants of human RTEF-1 transcripts are able to potentiate expression from the VEGF 5′ proximal promoter region.


  • Gene therapy for proliferative ocular diseases

    by Trevor J McFarland, Yi Zhang, Binoy Appukuttan, J Timothy Stout

    Proliferative ocular diseases encompass a wide variety of pathological processes with adverse cellular differentiation, proliferation and migration as common features. Pathologies may involve neovascular responses associated with diabetic retinopathy, retinopathy of prematurity or age-related macular degeneration. These diseases are quite prevalent and account for substantial visual impairment and blindness worldwide. Although treatment strategies are largely surgical, advances in our understanding of the proteins crucial to cell transdifferentiation, proliferation and migration, along with better gene transfer techniques, have greatly increased the potential for biological treatment options. In this report, the most common proliferative ocular vascular diseases and existing therapeutic modalities will be reviewed and an overview of possible gene therapy options will be discussed, along with potential candidate genes.


  • Corneal Transduction to Inhibit Angiogenesis and Graft Failure

    by Raghu C. Murthy, Trevor J. McFarland, Jon Yoken, Sandy Chen, Chris Barone, Dorthea Burke, Yi Zhang, Binoy Appukuttan, J. Timothy Stout

    Purpose. To test whether lentivirus-mediated expression of an endostatin::kringle-5 (E::K-5) fusion gene has an inhibitory effect on neovascularization and failure of corneal transplants. methods. A lentiviral vector containing a fusion transgene comprising the human endostatin gene and the kringle-5 domain of the human plasminogen gene (E::K-5) was used for transduction of corneal buttons ex vivo. The corneal buttons were transplanted after overnight incubation in media containing either lentivirus or PBS. Sixteen rabbits underwent allogenic penetrating keratoplasty in one eye. The area of neovascularization from the limbus to within the graft was documented after surgery. RT-PCR was performed to demonstrate the presence of transgene mRNA within the graft. Histopathology was used to analyze neovascularization, inflammation, and rejection morphology. results. Less neovascularization was observed in corneas treated with the lentivirus E::K-5 fusion vector. Early onset and profound neovascularization was observed in control eyes. E::K-5-treated animals did not have graft failure, whereas five of the six control animals had graft failure, as classified by opacification of the graft. All E::K-5 transduced corneas tested were positive by RT-PCR for the unique fusion gene sequence. Histopathology corroborated a significant increase of blood vessel presence and inflammatory reaction in control compared with treated eyes. conclusions. Corneas transduced with a lentivirus containing an endostatin::kringle-5 fusion gene demonstrated an inhibition of neovascularization and graft failure. E::K-5 gene transduction through a lentiviral vector system may be a useful adjunct to prevent graft neovascularization and corneal graft rejection in high-risk corneal transplants with antecedent rejection or neovascularization.


  • Retinal Tissue

    by Trevor McFarland, Binoy Appukuttan, J. Timothy Stout

  • Corneal Cells

    by Binoy Appukuttan, Trevor McFarland, J. Timothy Stout